Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 7, 2014; 20(41): 15007-15017
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15007
Table 2 Current indications of commonly used treatment options for hepatocellular carcinoma
Current indications
Hepatic resectionTreatment of choice in patients with resectable disease and absence of cirrhosis
Indicated in selected patients with limited disease and early cirrhosis (Child-Pugh A)
Limited role as a bridge to OLT
OLTStandard therapy for patients with HCC and Cirrhosis within Milan criteria
OLT may be indicated in select patients with tumors outside Milan criteria but within UCSF criteria
Indicated in select patients with stage III and IV HCC downstaged to within Milan criteria with use of neo-adjuvant therapy
Non resectional ablative therapies (RFA, microwave, TACE, TAE, HIFU etc.)Indicated as primary therapy only in patients with HCC who are not candidates for curative resection or OLT
Increasingly used alone or in combination as bridging therapy in patients awaiting OLT or to downstage stage advanced stage disease to within Milan criteria
Established role in palliative treatment of HCC (not discussed in this paper)